Adenosine is an endogenous modulator of several physiological functions in the central nervous system (CNS). The effect is mediated by a receptor family that consists of at least four subtypes: A 1 , A 2A , A 2B and A 3 receptors. The adenosine receptors play a role in neurological and psychiatric disorders such as Alzheimer's disease, Parkinson's disease, epilepsy and schizophrenia. Knowledge on adenosine receptor densities and status are important for understanding the mechanisms underlying the pathogenesis of diseases and for developing new therapeutics. Positron emission tomography (PET) offers a non-invasive tool to investigate these features in vivo, provided that suitable radiopharmaceuticals are available. This paper gives an overview of the current status on PET tracers for mapping adenosine receptors and the development of new compounds that may lead to new PET tracers.
INTRODUCTION
Adenosine is an endogenous modulator of a variety of physiological functions in the central nervous system (CNS) as well as in peripheral organs. The effect is mediated by the family of adenosine receptors, which are Gi/o-protein coupled receptors (coupled to ion channels, adenylyl cyclase or phospholipases) and consist of four subtypes designated A 1 , A 2A , A 2B and A 3 receptors (A 1 R, A 2A R, A 2B R and A 3 R, respectively) [1] [2] [3] [4] . For the last two decades, the A 1 R and A 2A R have been extensively studied biologically and pharmacologically. Increasing evidence emerges that A 2B R and A 3 R may be affected in pathophysiological events, and manipulations of adenosine receptors influence sleep and arousal, cognition and memory, neuronal damage and degeneration, as well as neuronal maturation [5] [6] [7] [8] 10] . There is growing evidence that each receptor subtype could also be a promising therapeutic target for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease and for other neurological pathologies such as epilepsy, ischaemic brain disorders or sleep disorders, as well as in a wide range of peripheral diseases, including cardiac ischaemic diseases, renal failure, immune and inflammatory disorders and cancer *Address correspondence to this author at the Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1, Naka, Itabashi, Tokyo, 173-0011, Japan; Tel: +81-3-3964-3241; Fax: +81-3-3964-2188; E-mail: ishiwata@pet.tmig.or.jp [6, [8] [9] [10] [11] [12] [13] [14] . The adenosine uptake site is also proposed as a therapeutic target [12, 15, 16] .
Many neuroreceptors have been visualized in vivo by positron emission tomography (PET) and single-photon emission computed tomography (SPECT) with the corresponding radioligands with high affinity and high selectivity. These techniques have been applied to evaluate physiological and pathophysiological states of the receptors in humans with and without neurological and psychiatric disorders [17] [18] [19] .
PET is a non-invasive technique to measure metabolic and functional processes in vivo in a quantitative way. By administration of radiopharmaceuticals, PET uses naturally occurring radionuclides that enable to prepare biologically active compounds in labeled form, so without affecting its properties by structural changes. The distribution throughout the body of the PET-radiopharmaceuticals can externally be measured in the tissues of interest as a function over time. Very useful for this purpose is 11 C. The use of the radionuclide 18 F (atom radius is comparable to a hydrogen atom) is an alternative in several cases. Radioactive half-lives of the most commonly used isotopes 11 C, 13 N, 15 O and 18 F are short, being 20, 10, 2 and 110 min, respectively. Therefore, repeated studies within a short time span are possible. Synthetic procedures for radiopharmaceuticals have to be rapid and a medical cyclotron and radiochemistry laboratory are required. The injected quantity (as expressed in mass units) of PET-tracers is very low (in the nanomolar range). Using these subpharmacological doses offers the possibility that highly potent compounds may be injected without any pharmacological effects. With PET, 3D-images are acquired yielding quantitative information on the distribution of the PET-tracers as a function of time. Spatial resolution for clinical PET-cameras is in the range of 4-8 mm, whereas this resolution for animal PET-scanners is 0.5-2 mm. To account for the fate of the tracer, kinetic modeling is applied. The tracer can either be free, or bound (specific or non-specific) or can be metabolized. Tracer kinetic modeling is a mathematical description of the fate of the tracer in the human body over time. Using PET, it is possible to measure parameters, such as enzyme activity, biosynthesis rate, and receptor density/occupancy.
In addition, PET is increasingly used as a tool in CNS drug discovery and development or evaluation of the efficacy of drugs [20] . PET assessment of the adenosine receptor system in the CNS probably offers us a new diagnostic tool for neurological and psychiatric disorders as well as an opportunity to understand the general neurotransmission system more profoundly. The early work on developing PET tracers for the adenosine receptor has been reviewed previously [21] [22] [23] . This paper describes an overview of the current status of the development of PET radioligands for mapping adenosine receptors and the development of new lead compounds for potential PET radioligands.
POST-MORTEM HUMAN BRAIN STUDIES ON ADENOSINE RECEPTORS
A limited number of studies of the postmortem human brains have been reported for the A 1 R and A 2A R adenosine receptors by both membrane and in vitro autoradiographic receptor binding methods, but not for A 2B R and A 3 R. First distribution of A 1 Rs was quantitatively assayed by Fastbom et al. [24] . Later, Svenningsson quantitatively visualized distribution of A 1 Rs and A 2A Rs in whole-hemisphere sections [25, 26] . A 1 Rs were widely distributed, with the highest densities in the striatum radiatum/pyramidale of the hippocampal region CA1. Jennings et al. found co-localization of adenosine uptake sites and A 1 Rs [27] , while Glass et al. reported slightly different distribution patterns in the hippocampus [28] . On the other hand, A 2A Rs were abundant in the putamen, nucleus caudatus, nucleus accumbens, and globus pallidus pars lateralis, and were also found in certain thalamic nuclei and throughout the cerebral cortex.
In patients with Alzheimer's disease, density of A 1 Rs was reduced in the hippocampus [29] [30] [31] [32] . However, the reduction was also observed in other types of dementia and was devoid of the specificity for Alzheimer's disease [33] . The decreased density of A 1 Rs was also observed in the caudate and putamen [34] . In patients suffering from temporal lobe epilepsy, upregulation of A 1 R (48% increase) was found in the neocortex by Angelatou et al. [35] , while Glass et al. found that the A 1 Rs were reduced in epileptic temporal cortex [36] .
As for A 2A Rs, in patients with Huntington's disease in which selective degeneration of the striatopallidal neurons is one of the pathological features, the density of A 2A Rs is significantly reduced in the striatum [37, 38] . The loss of A 2A Rs in the caudate nucleus, putamen and external globus pallidus was more predominant than that of dopamine D 2 receptor binding [38] . In patients with Parkinson's disease characterized by selective degeneration of nigrostriatal dopamine neurons, the density of A 2A Rs is not significantly affected [37] . In patients with schizophrenia, Kurumaji and Toru found a significant increase in the A 2A Rs in the caudate and putamen [39] . However, Deckert et al. reported that antipsychotic medication induced upregulation of striatal A 2A Rs [40] .
There are several limitations in the postmortem studies of brain disorders. The effect of tissue perfusion is excluded. The good preservation of the tissues is essential to avoid autolysis and the duration preserving the tissues may alter the findings. Furthermore, the progress of brain disorders cannot be followed in the same subjects. From these points of view, PET evaluation of the brain disorders has a much advantage for pathophysiological studies.
ADENOSINE A 1 RECEPTOR LIGANDS
Adenosine presynaptically inhibits the release of many neurotransmitters, especially excitatory ones such as the potentially excitotoxic amino acid glutamate. This effect of adenosine is mediated by presynaptic A 1 Rs linked via Gproteins to both calcium and potassium ion channels. Thus, A 1 Rs inhibit neuronal communication, and are the potential theraeutic target for neurodegenerative diseases such as Alzheimer's disease and for other neurological situation such as epilepsy. A large numbers of potent A 1 R agonists and antagonists with high affinity and high selectivity have been developed and reviewed [41] [42] [43] [44] [45] . Cyclohexyladenosine, an adenosine agonist, and other related nucleosides have high and selective affinity for A 1 Rs, and [
3 H]cyclohexyladenosine has been used in vitro as a standard radioligand for A 1 Rs [24, 28, 29, 34] . However, they are not appropriate ligands in vivo because of the low penetration of the blood-brain barrier. On the other hand, xanthine derivatives such as DPCPX [46, 47] and KF15372 [48, 49] are candidates for use as in vivo tracer for mapping the A 1 Rs in CNS. [ 3 H]DPCPX has been used in vitro as a radioligand with high and A 1 -selective affinity [25, [31] [32] [33] . Several PET ligands derived from xanthine derivatives have been evaluated (Fig. 1 , Table  1 ) and two of them have been used in clinical studies up to now. Recently, a nonxanthine-type PET ligand has been prepared from pyrazolopyridine analogs [50] . [60, 61] . Thus, after preclinical studies including dosimetry and toxicology [62] , [ 11 C]MPDX was moved further to clinical studies.
PET Ligands
Holschbach et al. examined a series of xanthine compounds based on DPCPX as a leading compound for developing radioligands for PET and SPECT, and found several candidates containing iodine or fluorine [63] . From these series, they prepared [ 18 F]CPFPX by nucleophilic substitution with [ 18 F]fluoride with a high radiochemical yield of 45% [64] , and found that [ 18 F]CPFPX showed high receptorspecific uptake (70-80%) in the brain of rodents in vivo [64, 69] . In a glioma bearing rat model, Bauer et al. found that the binding of [ 18 F]CPFPX was increased in a zone surrounding tumors (136%-146% as compared to control brain tissue) due to upregulation of A 1 R in activated astrocytes [65] . Furthermore in a preliminary study, the group demonstrated A 1 R occupancy by caffeine in the rat brain by PET with [ 18 F]CPFPX [66] .
Recently, Matsuya et al. proposed [ 11 C]FR194921, a highly selective, nonxanthine-type A 1 R antagonist [67] . The tracer was prepared with a high radiochemical yield (38% based on [ 11 C]methyl iodide), and showed receptor-specific uptake (50%) in the brain of rats in vivo. In PET imaging studies of the monkey brain, the images were similar to those of [ 11 C]MPDX (SUV = 3.05-3.5) [62] , but the radioactivity accumulated for 60 min (SUV = 0.5-0.7, calculated assuming the body weight of the monkeys to be 4-5 kg) and then slightly decreased, suggesting that the affinity for A 1 Rs may be too high for imaging in the time-frame of the PET scan using a 11 C-labeled tracer (60-90 min).
The other radioligand labeled with positron emitter was 5'-(methyl [ 75 Se]seleno)-N 6 -cyclopentyladenosine ( 75 Se, half life of 7.1 h) [68] , but the biological evaluation of the tracer has not been reported. 
Pharmacokinetic Modeling

Compartmental Analysis for Radioligands
A ligand carried by blood flow enters into a brain tissue by perfusion through the capillary wall. Then, a part of the ligand in tissue binds to and dissociates from the receptor sites dynamically. Since PET measures a total amount of ligand in tissues that contain both unbounded and bound ligands, some analytical approaches should be incorporated to determine receptor binding.
The behavior of ligand in tissues can be described using a compartmental model as shown in Fig. (2) [79, 80] . In the model, C p , represents concentrations of the ligand in arterial plasma, and C f and C b denote unbound and specifically bound ligand to a target receptor site, respectively. The blood-brain barrier (BBB) is located between C p and C f . Ligand transportation from capillary to tissues is described with K 1 [mL/min/g] containing a regional blood flow and permeability-surface product. k 2 [1/min] rate. Mathematically it is difficult to estimate B max . Instead, a binding potential (B p ) defined as k 3 /k 4 is utilized for quantification of a receptor density which corresponds to B max /K D , the ratio of the association and disassociation rate of a ligand.
In kinetic analysis, B p is estimated from the dynamic PET data C that is the sum of C f +C b and concurrently performed arterial blood sampling to derive C p . But, the estimation is a nonlinear optimization problem, which is not easy to do, and the calculation speed is slow. Therefore, a graphical approach of the Logan plot is usually employed.
Logan Plot
A Logan plot [81] is a simple and effective algorithm for receptor imaging. The operational equation of the Logan plot is obtained by integrating differential equations related to the compartment model; mathematical details are found in the equations (1) to (4) in [81] . As a summary, a linear relation is established between C and C p :
where the new quantity of D v corresponds to a distribution volume. Logan showed that some minutes after the administration of ligand, the y-intercept, becomes constant over time, and the slope of the plot gives D v [82] .
Then, B p can be obtained from distribution volumes under the two assumptions: existence of a region in the brain where the receptors are ignorable, and K 1 /k 2 is common in whole brain. The region is referred as a reference region, and the cerebellum is a typical reference region for several neuroreceptors such as dopamine D 2 receptors. Under these assumptions, K 1 /k 2 is calculated as the distribution volume in the reference region, and B p is computed as
The Logan plot is fast and robust because it can be implemented as an estimation of a line, and so it is suitable for receptor imaging. However, it requires arterial blood sampling to obtain C p . Arterial blood sampling requests an insertion of catheter into the brachial artery. This is sometimes painful and uncomfortable for patients, and has potential risks of infection, occlusion, bleeding, pseudoaneurysm, or thrombosis [83, 84] , thus it is preferable to omit arterial blood sampling for clinical situation. Some schemes were proposed: using predefined k 2 [85] , RPM in which mathematical reformulation is applied to the original compartmental model [86] , and EPICA where a statistical approach is utilized to extract C p from measured PET data [77, 87] .
A typical Logan plot is demonstrated in Fig. (3) . It is derived from [ 11 C]MPDX, and the slope in the striatum is larger than one in the cerebellum. 11 C]MPDX [74] . In the static images, the contrast between cerebellum and major cortices is lower than those in the basal ganglia. The Logan graphical analysis clearly visualized a spatial distribution of the A 1 Rs: low in the cerebellum and high in the basal ganglia which was reported in [24, 25, 69] . 
Medicinal Chemistry
A 1 Agonists
Several highly selective agonists for the A 1 R have been developed [42] [43] [44] . As is shown in Fig. (5) , all high affinity A 1 R agonists have a chemical structure that is derived from adenosine. Substitution at the N 6 and C2 position of the adenine moiety is allowed and could increase sensitivity and subtype selectivity. The ribose ring in these compounds is crucial for agonist activity and only minor alterations that the 5'-hydroxyl group are tolerated. Adenosine-5'-ethyluronamide (N-ethylcarboxamidoadenosine, NECA, A1-1a) is a 5'-substituted derivative of adenosine that is frequently used as an adenosine receptor agonist in binding assays. NECA can in principle be labeled with carbon-11 at the carbonyl group via an acylation reaction with [ 11 C]propanoic chloride, in an analogous manner as described for [ 11 C]WAY100635 [88] . However, [ 11 C]NECA would not be a suitable PET tracer, because it lacks subtype selectivity ( Table 2 ). Morrison and coworkers described a series of 5'-aromatic ethers and sulfides as potential A 1 R selective agonist [89] . Among these compounds, A1-1b, with a 2-fluorophenyl group at the 5'-position and a tetrahydrofuranyl moiety at N 6 , potentially could be converted into a PET tracer. It has a fairly high affinity for the A 1 R (K i = 12.7 nM), a favorable lipophilicity for brain penetration and an elimination half-life of 0.3 h, but its affinity for the other adenosine receptor subtypes is still unknown. Although compound A1-1b could -in theory -be labeled at the fluorophenyl group with high specific activity fluorine-18, this might prove difficult because the aromatic ring is not activated by electron withdrawing substituents that could facilitate a nucleophilic substitution reaction. Another drawback of compound A1-1b is that it shows some metabolism in vivo, resulting in formation of a high affinity full agonist after cleavage of the fluorophenyl group.
A2A-1 (YT-146)
A2A-2 (CGS 21680)
A3-2a, -2b, -2c
The N 6 -substituted adenosine derivatives CPA (A1-1c), CCPA (A1-1d) and R-PIA (A1-1e) are well-known A 1 R agonists with sub-nanomolar affinity, high subtype selectivity and appropriate lipophilicity [90] . Unfortunately, these compounds do not appear to have any positions that can be easily labeled with a positron-emitting isotope.
Beukers et al. investigated a series of adenosine derivatives that are substituted at the C2 position with various aminocarbonyltriazene groups [91] . In this series, labeling of agonist A1-1f at the methoxy group by methylation with [
11 C]methyl iodide or [ 11 C]methyl triflate seems feasible. However, the compound will probably not be suitable as a PET tracer, because its affinity and selectivity are insufficient. Moreover, compound A1-1f is probably not able to penetrate into the brain, as it was calculated to have a logP value of -1.0.
Thus, none of the available agonists appears to have favorable properties for a PET tracer for A 1 R imaging.
A 1 antagonists
A considerable number of A 1 R antagonists has been developed in the past decades, some of which may be converted into promising PET tracers. In Fig. (6) , a selection of potent A 1 R antagonists that can be labeled with carbon-11 is depicted. The A 1 R antagonists usually contain a polyheterocyclic core, but lack the ribose moiety that is essential for A 1 R agonists. The xanthine derivative DPCPX (Fig. 1) is probably the best-known potent A 1 R antagonist. It displays a 20 and 60-fold selectivity for the human A 1 R subtype over the A 2A R and A 3 R subtypes, respectively [52] . A possible drawback of DPCPX could be its relatively high lipophilicity, which may give rise to high levels of nonspecific binding. Bisserbe et al. first reported the potential of DPCPX as a PET probe for labeling A 1 Rs [51] . It displays a 20 and 60-fold selectivity for the human A 1 R subtype over the A 2A R and A 3 R subtypes, respectively (Fig. 1, Tables 1 and 2 ) [52] . They used the tritiated DPCPX and found that it exhibited preferable characteristics for a PET probe such as receptor-specific binding. The compound can potentially labeled by alkylation using [
11 C]propyl iodide [53] ; however, they did not advance further studies.
Bulicz et al. described a number of pyrido[2,3-d]pyrimidinediones as candidate A 1 R antagonists, of which compound A1-2 displayed highest potency and good A 1 /A 3 selectivity. Likewise, LUF5735 (A1-3) was presented as the most potent antagonist in a series of pyrimidine derivatives [92] . Compounds A1-2 and A1-3 can be transformed into PET tracers by [ 11 C]methylation of an N-methyl substituent and by [ 11 C]acylation at the amide function, respectively. Unfortunately, both compounds appear unsuitable as PET tracers, because of their high lipophilicity, causing a high extent of non-specific binding.
Among a series of substituted N 6 -cyclopentyl-adenine derivatives that were tested as antagonists for the A 1 R, LUF5608 (A1-4) displayed highest affinity [95] . The compound seems to have an acceptable logP of 2.9 and seems to be readily labeled by N-methylation. When the intrinsic activity of the compounds was determined in a [
35 S]GTP S binding assay in CHO cells expressing the human A 1 R at high density, LUF5608 and DCPCX proved to be an inverse agonist instead of a neutral antagonist.
A 1 Allosteric Enhancers
Allosteric enhancers of the adenosine receptor are compounds that augment the response of the receptor to adenosine or other agonists by stabilizing the agonist-receptor-G protein complex [20] . Consequently, the rate of dissociation of the agonist from the complex is reduced. Moreover, allosteric enhancers were suggested to stabilize the active conformation of the receptor even in the absence of an agonist. There is evidence that the A 1 R contains an allosteric binding site that is distinct from the agonist binding site [93] . PET imaging with radiolabeled allosteric enhancers may provide valuable information on the mode of action of these compounds. In this way the interaction of the allosteric enhancers with agonists can be measured using competition studies.
The thiophene derivative PD 81,723 (Fig. 7, A1-5a ) was among the first A 1 R selective allosteric enhancers to be discovered [20] . This enhancer, however, also displayed antagonistic properties and therefore is not suited as a PET tracer. Baraldi and coworkers synthesized a series of naphtyl derivatives of PD 81,723 [93] . In this series, compound A1-5b was the only representative with allosteric activity that could easily be labeled by [ 11 C]methylation of the methoxy stubstituent. Unfortunately, A1-5b is too lipophilic for a suitable PET tracer (logP 5.5).
Chordia et al. described a selection of 6-arylindeno[1,2-d]thiazoles with allosteric enhancer activities in the low micromolar to sub-micromolar range [96] . The representatives A1-6a, A1-6b and A1-6c exhibited more than 4-fold greater allosteric enhancement activity than PD 81,723, with an EC 50 that ranged from 0.9 to 2.2 μM. The free bases of these compounds, however, show only minor allosteric enhancement activity. In contrast to PD81,723, these compounds displayed only weak A 1 and A 3 antagonistic activity. The compounds are stable towards oxidation in DMSO solution for months and their chemical structures allow labeling by [ 11 C]methylation at oxygen or nitrogen. Thus, radiolabeled allosteric enhancers A1-6a, A1-6b and A1-6c warrant further investigation as PET tracers for the A 1 R allosteric binding site.
ADENOSINE A 2A RECEPTOR LIGANDS
A 2A Rs coupled with G-proteins exhibit a lower affinity to adenosine and enhance neuronal communication. They are restrictly distributed in the basal ganglia, particularly abundant in the striatum, which are thought to play a crucial role [98, 99] . On the other hand, starting from the non-selective adenosine antagonist CGS 15943 [100] , a number of nonxanthine polyheterocycles have also been synthesized as A 2A R antagonists. Development of A 2A R ligands has been reviewed in several articles [41, 101, 102] . Tritiated CGS 21680 (Fig. 5, A2A-2) is a standard radioligand in vitro for A 2A R assays [25, [37] [38] [39] [40] (Fig. 8, Table 3) , and only one xanthine-type ligand has been used in clinical studies by PET to date.
PET Ligands
First, a xanthine compound KF17837 developed by Suzuki and co-workers [98, 99, 103] [130] binding sites of an A 2A R radioligand in the cerebral cortex and hippocampus, and defined other A 2A R subtypes, atypical A 2A R, in contrast to the classical A 2A R in the striatum [114, 115] . In a rat model of degeneration of striatopallidal gamma-aminobutyric acid-ergic-enkephalin neurons induced by intrastriatal injection of quinolinic acid, a Huntington's disease model, degeneration of A 2A Rs in the lesioned striatum was detected by PET and ex vivo and in vitro autoradio- The tracers accumulated slightly more in the striatum than in other regions of the brain, but the uptake ratios of striatum to other regions were low. In addition, the tracers not only exhibited specific binding to A 2A R in the target striatum, but also had specific binding to a certain extent and/or high nonspecific binding in the non-target tissues such as the cerebral cortex and cerebellum. Moreover, the search for radioligands with more pronounced A 2A R-selectivity, in other words much less affinity for non-target tissues, led to [ 11 C]KF21213 [122] . In mice, the uptake ratio of striatum to cortex and striatum to cerebellum increased to 8.6 and 10.5, respectively, at 60 min postinjection, and the A 2A R-specific uptake was not detected in the cerebral cortex and cerebellum. All of the xanthine-type radioligands described above were prepared by N-or O-methylation of the corresponding demethyl compounds using [ 11 C]methyl iodide with high radiochemical yields suitable for routine clinical use. As the methylating agent, [ 11 C]methyl triflate could be also used more efficiently as shown for the synthesis of [ 11 C]TMSX [128] . On the other hand, it should be noted that a styryl group in xanthine derivatives is isomerized by exposure to visible light to form a stable equilibrium mixture of E-isomer and Z-isomer and the Z-isomer is less active than the Eisomer [129] . Therefore, in the experimental and clinical studies, all procedures from radiosynthesis to metabolites analysis of plasma samples of animals or humans for quantitative evaluation of ligand-receptor binding, should be carefully done under the exclusion of light [118] .
As for the non-xanthine type radioligands, Todde et al.
proposed [ 11 C]SCH442416 derived from SCH 58261 [130] . In rats, the level of radioactivity in the striatum increased for the first 15 min after the injection of [ 11 C]SCH442416 and, then gradually decreased. The maximal uptake ratios of striatum to cortex or to cerebellum were 4.6 at 15 min postinjection. Using various ligands, Moresco et al. [131] demonstrated in a blocking study in rats that the striatal uptake of 
Clinical Studies
The first visualization of A 2A Rs in the human brain was reported by Ishiwata and co-workers using [ 11 C]TMSX PET, and was compared with dopamine D 2 receptors ([ 11 C]raclopride PET) and A 1 Rs ([ 11 C]MPDX PET) [132] . They demonstrated that infusion of theophylline reduced the [ 11 C]TMSX-binding evaluated Dv.
The group preliminary applied [ 11 C]TMSX PET to Parkinson's disease. Fig. (9) [133] .
In early Parkinson's disease, release of dopamine is asymmetrically affected. In the patient in this study, the symptoms of Parkinson's disease were right dominant. The left-side dopamine transporter was more decreased than the 
Medicinal Chemistry
A 2A Agonists
Promising candidate agonists for PET-labeling have not been described in the literature thus far. Potent A 2A R subtype selective compounds have been reported but none of these are amenable for labeling with carbone-11 or fluorine-18. An example is YT-146 (A2A-1, Fig. 5) , an octynyl derivative of adenosine, which has an appropriate logP value and a fairly good selectivity of A 2A over A 1 . An A 2A R subtype selective agonist that can be labeled in the ethyl group is the established compound CGS 21680 (A2A-2). This compound is used as a standard for A 2A R in in vitro studies, but the low log P value will make the PET-labeled form of CGS 21680 not suitable for investigating cerebral adenosine receptors.
A 2A Antagonists
Antagonists for this receptor subtype can be divided in two main categories, i.e. xanthine-type and polyheterocyclic compounds. A 2A R antagonists are orally effective in a variety of rodent models of Parkinson's disease [13] . Extensive optimization among the xanthine derivatives has already led to the clinical candidate KW-6002 (Fig. 8) (Kyowa Hakko Kogyo Co Ltd) [124] [125] [126] [127] , which was labeled with carbon-11 (see section 4.1). However, there is an increasing interest among researchers in this field to explore other classes of compounds as potential antagonists for this particular receptor.
From both classes of compounds potent and selective candidates have emerged that are amenable for labelling with carbon-11 or fluorine-18 (Fig. 10) . These compounds have high affinity, selectivity and a suitable lipophilicity to penetrate the blood brain barrier. The selectivity is based on A 1 and A 2A affinities, and no affinities for A 2B or A 3 have been determined. As described above, most obvious labeling possibilities are [ 11 C]methylation of one of the aromatic methoxy groups or the N-methyl in the xanthine part. The 11 C-labeling procedure for this N-methyl group has been developed for other xanthines previously and can be applied to candidate A2A-3 [173] .
Several potent candidates from the polyheterocyclic class have also been proposed. These compounds have excellent A 2A over A 1 selectivity and logP values ranging from 0.6 to 3.3. These compounds can be labeled with carbon-11 or fluorine-18, but as illustrated for compounds (A2A-7, -8 and -12) evaluated by Holschbach et al. [135, 136] , these properties are no guarantee to become a useful PET-tracer. In particular the compounds as described by Minetti [141, 142] are candidates for PETlabeling. 
ADENOSINE A 2B RECEPTOR
Introduction
While the A 1 R, A 2A R and A 3 R have been pharmacologically characterized through the use of highly potent and selective agonists and/or antagonists, the study of the A 2B R subtype has been precluded due to the lack of selective ligands, and the absence of an appropriate binding assay. To date, the most potent, but nonselective, agonist for this subtype is NECA ( Table 2) , with affinity in the micromolar range [4] . No PET tracer for this subtype has been described so far.
The A 2B R has been implied in vascularization, cell proliferation, differentiation and in mast-cell-mediated activation of angiogenesis. This last effect is the result of a cooperative action of the A 2 Rs [143] . Peripherally, activation of the receptor leads to release of inflammatory cytokines. Antagonists are believed to be useful in the treatment of asthma.
It has not been demonstrated whether A 2B Rs are present in the brain or what their function would be. For the sake of completeness and anticipating to possible future applications for the A 2B R subtype for neuroscience, some potential compounds will be described in section 5.2.
Medicinal Chemistry
Regarding suitable agonists, no compound has been reported that has high affinity, selectivity or an acceptable lipophilicity and is amenable for labeling with carbon-11 or fluorine-18.
With respect to antagonists, several candidates draw attention ( Table 4 , Fig. 11) . Except for OSIP-339391 (A2B-6) [174] , all compounds belong to the class of xanthines. A2B-1 has very high affinity for the A 2B R, but for the other adenosine receptor subtypes, affinities are very low [175] . The xanthine moiety contains 2 N-methyl groups. One of these could be replaced by an [ 11 C]methyl group. Replacement of the CF 3 -group in A2B-1 by a fluorine atom decreases the affinity and selectivity for the A 2B R but may still yield a suitable PET-tracer that may be labeled with fluorine-18 (A2B-2) [176] .
Ilas et al. reported potent A 2B R ligands for electron paramagnetic resonance [144] . Ji et al. developed quite analogous compounds by replacing the radical part in A2B-3 by a cyanophenyl group (A2B-5) [145] . This compound displayed even higher affinity for the A 2B R and retained its selectivity, but has a high logP possibly resulting in high nonspecific binding. A2B-4 as reported by Baraldi et al. offers labeling possibilities by N-methylation with [
11 C]methyl iodide or [
11 C]methyl triflate on the pyrazole ring [146] . An alternative approach could be [
11 C]propylation on the amidic nitrogens in the xanthine ring. Finally, OSIP-339391 has the highest affinity and a good selectivity for the A 2B R. PETlabeling may be possible by [ 11 C]acetylation.
ADENOSINE A 3 RECEPTOR 6.1. Introduction
Among the human adenosine receptor subtypes, the A 3 R subtype was most recently characterized [7, 8, 147] . The A 3 R is a 318 amino acid protein that exhibits only 72% and Fig. (11) . Adenosine A 2B receptor antagonists.
85% sequence homology with its rat and sheep equivalents, respectively. The tissue distribution of the A 3 R mRNA is considerably different from the distribution of other human adenosine receptor subtypes and the rat A 3 R. Highest expression of the human A 3 R was found in the lung and liver, moderate expression in the brain, aorta and testis and no detectable expression in spleen or kidney. Although only little is known about the physiological function of the A 3 R in the CNS, some evidence indicates that the receptor is involved in neuroprotection and neurodegeneration. For example, chronic treatment with an A 3 R agonist resulted in a reduction of post-ischemic cerebral damage, whereas acute treatment had an adverse effect [148] . Moreover, activation of the A 3 R on astrocytes was found to induce the release of neurotrophic factors that reduce neuronal damage [149] . The neuroprotective role of the receptor was also demonstrated in A 3 R knock-out mice, which were more vunerable to neuronal damage after CO-induced hypoxia than wild-type animals [150] . Thus, intervention at the A 3 R could provide an attractive strategy for treatment of brain injury. In addition, selective A 3 R antagonists have been proposed as potential drugs for the treatment of asthma and inflammation.
Despite the fact that the A 3 R is an interesting target for imaging, no PET tracers for this receptor have been described so far. However, a number of high affinity A 3 R ligands that are amenable for labeling with carbon-11, fluorine-18 or iodine-124 have been described. The most promising candidates will be discussed in the following paragraph. 
A 3 Agonists
The majority of selective A 3 R agonists are N 6 and/or C2 substituted adenosine derivatives with an N-methylamide substituent at the 5' position. In theory, a carbon-11 label can be introduced in these compounds by N-methylation. The miodobenzyl derivative IB-MECA (A3-1a) is an important lead compound for A 3 R agonists (Table 2, Fig. 5 . IB-MECA is in phase II clinical trials for the treatment of colorectal cancer and rheumatoid arthritis now, but it is only moderately selective for the A 3 R subtype and therefore not an ideal candidate for a PET tracer. The A 1 /A 3 selectivity was increased by substitution of a chlorine atom at C2, as in Cl-IB-MECA (A3-1b), although the affinity for the A 3 R was slightly reduced [151] . When the oxygen atom in the ribose ring is additionally replaced by sulfur, as in A3-1c, the affinity and selectivity is further increased [152] . Besides labeling with carbon-11, the m-iodobenzyl substituent also allows labeling of compounds A3-1a, -1b and -1c with iodine isotopes for SPECT imaging or with the long-lived PET isotope iodine-124 (half-life of 4.18 days). The most potent and A 3 -selective thioadenosine derivative that was reported by Jeong and coworkers, was the N 6 -methyl compound LJ530 (A3-1d) [152] , which can be labeled with carbon-11 either at the 5'-amide or at N 6 . Unfortunately, this compound appears too hydrophilic (logP 0.5) for brain penetration.
A 3 R binding is favored when the ribose ring is in the 2'-exo-(N) twist conformation. As an approach to increase A 3 -selectivity by increasing the rigidity of the ribose moiety, Tchilibon et al. prepared a series of 2,N 6 -disubstituted (N)-methanocarba adenosine derivatives [153] . Compounds A3-2a, -2b and -2c are some representatives from this study with a high affinity and selectivity for the A 3 R. These compounds are readily labeled by [ 11 C]methylation at the methoxy group. In addition, compound A3-2c can also be labeled with various iodine isotopes for SPECT or PET. Based on the lipophilicity of these compounds, iodide A3-2c seems to be the most likely candidate as a PET tracer for imaging the CNS A 3 R.
A 3 Antagonists
In contrast to the strict structural limitations of A 3 R agonists, highly potent antagonists of this receptor subtype from various distinct classes of compounds have been described. Baraldi and coworkers prepared several pyrazolo [4,3, -e]-1,2,4-triazolo [1,5-c] pyrimidine derivatives [146] . From these compounds, A3-3a and -3b were depicted in Fig. (12) and Table 4 , as highly potent representatives with high selectivity for the A 3 R. Both substances can be labeled with carbon-11 and have favorable lipophilicity for crossing the bloodbrain-barrier. To increase the water solubility of these compounds, positively charged pyridine substituents were attached to the carbamate moiety, resulting in e.g. compound A3-3c [154] . This compound had an exceptionally high affinity and selectivity for the A 3 R, but it is unclear whether this charged compound could penetrate the brain. The free base of A3-3c had similar affinity and selectivity as the hydrochloride salt and a logP of 1.1. The closely related compounds A3-4a, -4b and -4c are representatives of the 1,2,4-triazole[5,1-i]purine class of A 3 R antagonist that were published by Okamura et al. [155] . These antagonists have subnanomolar affinity and excellent selectivity for the A 3 R subtype. Purines A3-4b and -4c are amenable for [ 11 C]methylation, whereas A3-4a can be labeled by nucleophilic substitution with [ 18 F]fluoride. The imidazopuridinone derivative PSB-11 (A3-5) was described by Müller et al. as a high affinity, selective A 3 antagonist that is approximately 4 times more potent than its S-enantiomer [156] . PSB-11 was radiolabeled with tritium and applied in binding assays [157] . Remarkably, non-specific binding of [ 3 H]PSB-11 in these assays was extraordinary low (approximately 2%). PSB-11 might therefore be an attractive candidate PET tracer, as it can readily be labeled by N-[
11 C]methylation.
The structurally closely related pyrazolo[3,4-c]quinoline A3-6 [158] and 1,2,4-triazolo [4,3-a] quinoxaline A3-7 [159] , the isoquinoline VUF5574 (A3-8) [160] , the thiazole A3-9a and the thiadiazole A3-9b [161] have a methoxy substituent that can be exploited for labeling with carbon-11. All these compounds have an affinity for the A 3 R in the low nanomolar range and all are highly selective antagonist for this receptor subtype. Compounds A3-6, -8, -9a and -9b seem to have a favorable lipophilicity for brain imaging, whereas the logP of A3-7 may be to low for brain penetration.
Finally, Li and coworkers reported various substituted pyridine derivatives as selective A 3 antagonists, such as fluoride A3-10 [162] and methoxy compound A3-11 [163] . These pyridine derivatives, however, are not likely candidates for PET tracers, because of their high lipophilicity.
A 3 Allosteric Enhancers
Isoquinoline derivative VUF5455 (A3-12) was among the first allosteric enhancers of the A 3 R to be discovered [164] and can readily be labeled by [ 11 C]methylation at the methoxy group (Fig. 7) . VUF5455 significantly reduced the dissociation rate of an A 3 agonist, but did not affect the dissociation of an A 3 antagonist. VUF5455 did not show any binding to the A 1 R and A 2A R, but it had a weak affinity for the binding site of the A 3 R.
Quinoline derivative DU124,183 has been used as a lead compound for allosteric enhancers of the A 3 R, but it can not easily be labeled with carbon-11. Compound A3-13 is the methoxy-substituted analogue of DU124,183, in which a [ 11 C]methyl group can be introduced at the methoxy substituent. Compound A3-13 exhibits similar allosteric enhancement activity as DU124, 183 and hardly displays any affinity for the binding sites of the different adenosine receptor subtypes [165] .
A potential drawback for application of radiolabeled VUF5455 or A3-13 as a PET tracer could be their relatively high lipophilicity (logP 3.6 and 3.7, respectively).
ADENOSINE UPTAKE SITE
Introduction
Hydrophilic nucleosides, including adenosine, rely on carrier proteins for their transport across membranes [166] . Two families of transporters have been identified, the equilibrative and concentrative nucleoside transporters (ENT and CNT, respectively). Although nucleoside salvage is the main function of the transporter, recent data indicate functions beyond metabolic recycling. In the brain and spinal cord, for example, the transporters regulate synaptic levels of neuroactive purines, such as adenosine, and thus have effect on physiological processes modulated through G-coupled adenosine receptors. Novel identified functions of the transporters within CNS are related to sleep, arousal, addiction, nociception and analgesia.
Regarding ENTs, two subtypes have been characterized, the es (equilibrative sensitive), also known as ENT1 and the ei (equilibrative insensitive) transporter, ENT2 [166] . These differences are based on the (in)sensitivity to inhibition by S 6 -(4-nitrobenzyl)-mercaptopurine riboside (AUS-1a, also called 4-nitrobenzylthioinoisine, NBTI), and dipyridamole (AUS-2), a non-nucleoside, that inhibits both ENT1 and ENT2 (Fig. 13) . Both NBTI and dipyridamole inhibit ENT1 at low nanomolar concentrations. Recently, two new subtypes, ENT3 and ENT4 were identified, but not yet characterized. ENTs are distributed all over the mammalian tissues, whereas the CNTs are especially abundant in the intestine, kidney, and liver. The CNT proteins can be divided in 3 subtypes, CNT1, CNT2, and CNT3. CNTs are insensitive towards inhibition by NBTI.
PET ligands
For PET-imaging only two papers appeared. [1-methyl-11 
) with a K i value of 13 nM was prepared by N-[ 11 C] methylation (Fig. 14) [167] . In biodistribution studies, the highest uptake was found in the liver, followed by the kidney and small intestine, and carrier-saturable uptake was observed only in the liver (about 30%). Although the brain uptake was very low in vivo probably because of relatively high lipophilicity (logP 3.6), in vitro autoradiography showed binding of [ 11 C]KF21562 to adenosine transporters with a high fraction of nonspecific binding (specific binding, less than 25% of total binding).
The other labeled tracer is [ 11 C]adenosine monophosphate ([ 11 C]AMP) [168] . Extracellular adenylates undergo rapid conversion: ATP -> ADP -> AMP -> adenosine, followed by cellular uptake and intracellular rephosphorylation to ATP. Adenylate imaging of cancer would be possible because of increased import/export of radiolabeled adenylates associated with tumor metabolism as well as adenylate interactions with adenosine receptors. amino-imidazolyl-carboxamide (Fig. 14) . Besides biodistribution studies, the effect on [
11 C]AMP uptake by blocking with dipyridamole was investigated. At 60 min postinjection lung uptake was reduced to about 40%. Uptake of [ 11 C]AMP was highest in the lung, blood and heart. The value of this radioligand need to be further investigated.
Medicinal Chemistry
KF24345 (AUS-3) was developed as a novel antiinflammatory agent and binds to both ENT1 and ENT2 (Fig.  13) [169] . As NBTI (K i of 0.7 nM) the K i for ENT1 was 0.4 nM, but KF24345 was 50-fold more effective at blocking ENT2 (K i of 100 nM). KF24345 is an interesting candidate for PET-labeling. [ 11 C]Methylation on the amidic nitrogen is a potential labeling strategy.
A related series of analogs was developed with alkylamino substituents at the purine ring [170] , aiming to prepare less polar compounds than NBTI (logP 1.20) . This polar nature hinders its oral availability and passage through the blood brain barrier. It was shown that the addition of this alkylamino group had the concomitant advantage that affinity was greatly increased. K i values were in the nanomolar range, whereas without alkylamino these values were 53 nM. From the point of view of development of a PET-ligand, the NHMe compound is to be preferred, but increasing the alkyl group to ethyl or propyl further increases lipophilicity and affinity. In fact, introduction of the NH-methyl and NH-ethyl groups results in more polar compounds (AUS-1b and AUS1c, K i values of 28 nM and 9.5 nM, respectively) (logP 0.64 and 1.17, respectively). Larger alkyl groups, such as cyclohexyl, result in even more potent and lipophilic substances.
Another modification to increase effectiveness has been investigated by Gupte et al. [171] . Starting from NBTI as a lead compound, the nitro group was replaced by halogens in ortho, meta and para position. All the para-compounds with Br, Cl, I and F yielded the most potent inhibitors with K i values in the nanomolar range. The 4-fluoro compound (AUS-1d), a candidate for 18 F-labeling with a logP of 1.52, has a K i of 9.02 nM. Alternatively, 124 I-labeling would yield a compound (AUS-1e) with a K i of 3.88 nM.
CONCLUSION
Development of high-affinity and subtype-selective ligands for adenosine receptors for last two decades has enabled quantitative measurement of A 1 Rs of the human brain by PET using [ 18 F]CPFPX or [ 11 C]MPDX as an in vivo probe. The PET using these two tracers could be applied to evaluate the pathophysiological states of the receptors in humans with neurological and psychiatric disorders. Preliminary data on mapping of A 2A Rs in the human brain were generated using [ 11 C]TMSX, but more studies are essential for establishing the method. On the other hand, in spite of increasing evidence charactering pathophysiological events in the other subtypes, A 2B R and A 3 R, and adenosine uptake site, their function has not clearly understood yet, and there were only limited trials for developing PET ligands for these 
